Company intelligence / Profile preview

Babyl

Ownership: Private
Development stage: Commercial

Overview

Babyl/Babylon provided millions of digital consultations globally using an AI-powered virtual healthcare platform. In Rwanda alone, over 3.5 million consultations were performed with more than 2.5 million registered users before the service began winding down in mid-to-late 2023[1][2]. The company’s clinical results focused on access and efficiency metrics rather than traditional clinical trial outcomes. No drug or device pipeline. The company’s model was recognized for improving access to primary care through digital means. As of late 2023/early 2024 there are no ongoing programs due to wind-down/closure.

Therapeutic areas: Other
Modalities: Non-pharmacological therapyDevice
Industry: Non-Academic Healthcare

Partnerships

Government of RwandaNHS England ("GP at Hand")CentenePrudential AsiaBupaMount Sinai Health PartnersBill & Melinda Gates FoundationTelus Health

Beyond the preview

Go deeper on Babyl.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Babyl.

Explore the full profile